Alto Neuroscience, Inc. 8-K

What Happened

Alto Neuroscience, Inc. announced on March 16, 2026 that it entered into a Securities Purchase Agreement to raise approximately $120.0 million in a private placement. The company agreed to sell 2,900,000 shares of common stock and issue pre‑funded warrants exercisable for 3,100,000 additional shares to certain institutional investors. The purchase price per common share is $20.00; the pre‑funded warrants were sold for $20.00 minus $0.0001 and have a per‑share exercise price of $0.0001. The Company engaged placement agents (including Jefferies and BofA Securities) and agreed to expand its Board of Directors to seven members effective March 16, 2026.

Key Details

• Gross proceeds expected: approximately $120.0 million (before expenses).
• Securities to be issued: 2,900,000 common shares and pre‑funded warrants for 3,100,000 shares.
• Price and warrant terms: $20.00 per common share; pre‑funded warrants sold at $20.00 − $0.0001 and exercisable at $0.0001 per share; warrants do not expire.
• Registration/rights: Company must file registration statement within 30 days after closing; if not timely filed or declared effective, liquidated damages equal to 1.0% of each purchaser’s investment per 30‑day period (subject to caps) apply.

Why It Matters

This filing documents a significant equity financing that will increase Alto’s cash resources by roughly $120 million, which investors typically view as supporting the company’s operations and programs. At the same time, the issuance of new shares and the eventual exercise of pre‑funded warrants will dilute existing shareholders. The pre‑funded warrants have a nominal exercise price and include a default beneficial ownership limit (19.9%) that holders can adjust with notice. Finally, the registration rights mean the new investors expect resale registration soon; missed filing or effectiveness deadlines could trigger penalty payments by the company.